LG CNS Unveils Advanced AX Manufacturing Solutions for Pharma Sector at CPHI Milan 2026

Introduction

LG CNS, a leading AI transformation company based in Korea, has taken a significant step toward revolutionizing the pharmaceutical manufacturing landscape. At the CPHI Milan 2026, the world's largest pharmaceutical and biotechnology trade fair, LG CNS presented its range of Advanced AX (Artificial Intelligence Transformation) manufacturing solutions tailored specifically for the pharmaceutical industry. This showcase highlights the company's commitment to enhancing efficiency and automation within pharmaceutical manufacturing processes.

Overview of CPHI Milan 2026

The CPHI event is a prestigious gathering in the pharmaceutical and biotech sectors, attracting approximately 60,000 visitors and around 3,000 companies from over 160 nations. Being the flagship event for CPHI, it offers a platform for industry leaders to converge and discuss the latest technological advancements and trends in pharmaceuticals and biotechnology. This year, LG CNS is the only Korean company participating in the newly established 'AI Tech' zone, underscoring its innovative position in the industry.

Focus on Autonomous Pharmaceutical Factories

Under the banner of "Autonomous Factories in the Pharmaceutical Sector," LG CNS's stand prominently features three smart factory solutions that integrate plant design, production operations, and quality management. These solutions aim to support pharmaceutical and biotech firms that are expanding or building manufacturing facilities, facilitating every aspect from plant construction to ongoing operations.

The Role of Virtual Twins

In the manufacturing design phase, LG CNS introduced Factova Worldworks, a virtual validation simulator that utilizes digital twin technology to create a virtual replica of a real factory. This tool provides a 3D model of the facility layout to assess the optimal positioning of manufacturing equipment, the workflow of operators within the planned environment, and logistical routes for raw materials. Given the strict separation of areas within pharmaceutical manufacturing environments—such as sterile rooms and production zones—planning access routes in advance becomes particularly critical to maintain compliance and avoid contamination.

Streamlining Production Operations

The next phase introduces Factova Control, a solution designed for standardizing data and controlling equipment during production. This platform automatically converts process data—such as raw material identification numbers and formulations—into a unified format, ensuring consistent data usage across all manufacturing stages. This facilitates immediate responsiveness for clients when incorporating new equipment or adjusting workflows. Furthermore, it employs artificial intelligence to detect equipment anomalies and predict failures by analyzing real-time electrical, temperature, and vibration data, enabling proactive maintenance and reducing downtime.

Enhancing Quality Management

The quality management solution analyzes various data points, including production volumes, variations in raw material temperatures, and equipment operational histories, to identify potential quality issues. It seamlessly manages everything from root cause analysis to follow-up actions once problems are detected. Notably, when an anomaly is detected mid-process, the system promptly calculates alternative solutions and applies them in subsequent production phases to prevent defective product output. An AI-trained model compiles the Annual Product Quality Review (APQR) report, automating what used to be a lengthy and manual data collection and verification process, effectively reducing the time spent on this task by over 90%.

Commitment to Pharmaceutical Innovations

Eddie Jang, Head of the Chemical and Battery Product Division at LG CNS, emphasized, "The AX manufacturing solutions we presented at this exhibition are tailored specifically for the pharmaceutical sector, enabling us to assist clients in automating all processes, from plant design to quality management. As a comprehensive solution provider encompassing all areas of manufacturing, we will continue to leverage our advanced solutions to meet the challenges in developing pharmaceutical production facilities that require precision and stringent quality standards, ultimately helping our clients produce medications more efficiently and automatically."

Conclusion

As LG CNS continues to pioneer advancements in the field of manufacturing through AI transformation, its participation in CPHI Milan 2026 not only showcases its innovative solutions but also reinforces its commitment to enhancing the pharmaceutical industry. With a focus on smart manufacturing and operational excellence, LG CNS is setting new benchmarks for quality and efficiency in pharmaceutical production. For more information, visit LG CNS.